Patents by Inventor Jonas Lidholm
Jonas Lidholm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220241406Abstract: The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.Type: ApplicationFiled: July 2, 2020Publication date: August 4, 2022Inventors: Jonas LIDHOLM, Lars MATTSSON, Angelica EHRENBERG, Håkan LARSSON, Jonas ÖSTLING
-
Patent number: 10753946Abstract: The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.Type: GrantFiled: July 20, 2015Date of Patent: August 25, 2020Assignee: PHADIA ABInventors: Lars Mattsson, Ulrica Olsson, Thomas Lundgren, Jonas Lidholm, Håkan Larsson
-
Patent number: 9757447Abstract: Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.Type: GrantFiled: December 30, 2015Date of Patent: September 12, 2017Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Patent number: 9724407Abstract: A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.Type: GrantFiled: September 29, 2015Date of Patent: August 8, 2017Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20170219602Abstract: The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.Type: ApplicationFiled: July 20, 2015Publication date: August 3, 2017Applicant: PHADIA ABInventors: Lars MATTSSON, Ulrica OLSSON, Thomas LUNDGREN, Jonas LIDHOLM, Håkan LARSSON
-
Patent number: 9518987Abstract: Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.Type: GrantFiled: November 3, 2015Date of Patent: December 13, 2016Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Publication number: 20160114031Abstract: Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.Type: ApplicationFiled: December 30, 2015Publication date: April 28, 2016Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20160082101Abstract: A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.Type: ApplicationFiled: September 29, 2015Publication date: March 24, 2016Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Patent number: 9274114Abstract: Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.Type: GrantFiled: May 13, 2014Date of Patent: March 1, 2016Assignee: Phadia ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Publication number: 20160051666Abstract: Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.Type: ApplicationFiled: November 3, 2015Publication date: February 25, 2016Inventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Patent number: 9243045Abstract: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.Type: GrantFiled: June 4, 2010Date of Patent: January 26, 2016Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Patent number: 9182400Abstract: Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.Type: GrantFiled: December 21, 2007Date of Patent: November 10, 2015Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Patent number: 9164101Abstract: An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.Type: GrantFiled: April 26, 2011Date of Patent: October 20, 2015Assignee: Phadia ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20140249048Abstract: Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: Phadia ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Publication number: 20130045233Abstract: An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.Type: ApplicationFiled: April 26, 2011Publication date: February 21, 2013Applicant: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20120076826Abstract: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.Type: ApplicationFiled: June 4, 2010Publication date: March 29, 2012Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20100129409Abstract: Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.Type: ApplicationFiled: December 21, 2007Publication date: May 27, 2010Inventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Patent number: 7279295Abstract: The present invention relates to a novel allergen from timothy grass (Phleum pretense) pollen, Phl p11 as disclosed in SEQ ID NO:2, and use thereof as a reagent and in a diagnositic kit as well as for immunotherapy.Type: GrantFiled: March 27, 2003Date of Patent: October 9, 2007Assignee: Phadia ABInventors: Asa Marknell Dewitt, Verena Niederberger, Pirjo Lehtonen, Susanne Spitzauer, Wolfgang R. Sperr, Peter Valent, Rudolf Valenta, Jonas Lidholm
-
Publication number: 20040014155Abstract: The present invention relates to a novel allergen from timothy grass (Phleum pratense) pollen, Phl p 11 as disclosed in SEQ ID NO 1, and use thereof as a reagent and in a diagnostic kit as well as for immunotherapy.Type: ApplicationFiled: March 27, 2003Publication date: January 22, 2004Applicant: Pharmacia Diagnostics ABInventors: Asa Marknell Dewitt, Verena Niederberger, Pirjo Lehtonen, Susanne Spitzauer, Wolfgang R. Sperr, Peter Valent, Rudolf Valenta, Jonas Lidholm
-
Publication number: 20030031685Abstract: The present invention relates to the use of an isolated allergen component in a serological assay for improved precision in the identification of the actual sensitizer in diagnosis of allergy. This enables not only adequate measures for avoidance of the causative agent but also appropriate selection of treatment of the allergic disease.Type: ApplicationFiled: December 21, 2001Publication date: February 13, 2003Inventors: Sabine Stumvoll, Jonas Lidholm, Kerstin Westritschnig, Susanne Spitzauer, Dietrich Kraft, Domenico Geraci, Rudolf Valenta, Paolo Colombo, Giovanni Duro